Cytokinetics Inc CYTK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
-
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
-
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
-
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
-
Cytokinetics to Participate in September Investor Conferences
Trading Information
- Previous Close Price
- $63.95
- Day Range
- $62.63–64.77
- 52-Week Range
- $54.31–88.05
- Bid/Ask
- $62.60 / $62.71
- Shares Outstanding
- 139.02M
- Market Cap
- $8.74B
- Volume/Avg
- 483,724 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 117.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 673
- Website
- https://www.cytokinetics.com
Competitors
Valuation
|
Metric
|
CYTK
|
SNY
|
BMY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 11.76 | 9.50 |
Price/Book Value | — | 1.37 | 5.64 |
Price/Sales | 117.62 | 1.76 | 2.56 |
Price/Cash Flow | — | 7.27 | 8.49 |
Price/Earnings
CYTK
SNY
BMY
Financial Strength
|
Metric
|
CYTK
|
SNY
|
BMY
|
|---|---|---|---|
Quick Ratio | 6.56 | 0.49 | 1.29 |
Current Ratio | 6.66 | 0.99 | 1.53 |
Interest Coverage | −6.54 | 8.05 | 7.88 |
Quick Ratio
CYTK
SNY
BMY
Profitability
|
Metric
|
CYTK
|
SNY
|
BMY
|
|---|---|---|---|
Return on Assets (Normalized) | −44.45% | 7.96% | 14.59% |
Return on Equity (Normalized) | — | 14.96% | 68.67% |
Return on Invested Capital (Normalized) | −85.02% | 11.28% | 21.69% |
Return on Assets
CYTK
SNY
BMY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?GX$kj | LOCK|&g%l> | $130B | |||
| Moderna Inc
MRNA
| LOCK|^^RS@D | LOCK|#ZL | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|QH#Nyks | LOCK|mxc$^ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|J&xmlB | LOCK|N! | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|sRj$L^ | LOCK|m^ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Rt<^&d | LOCK|Kwj?B | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&vDF&xr | LOCK|P<<w! | $28B | |||
| Incyte Corp
INCY
| LOCK|!Z<t@hw | LOCK|^% | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|^pZ>#& | LOCK|?q | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|n?sQNS | LOCK|KG | $14B |
United States